title: [Antithrombotics (Antithrombin therapy)].
abstract: Thrombus on the atherosclerotic plaque is mainly responsible for acute coronary syndromes. Antithrombin therapy continues to be the mainstay of the therapy defeating thrombus. Up-to-date antithrombin therapy consists of vitamin K antagonists, unfractionated and low molecular heparins, direct thrombin inhibitors and selective inhibitors of factor Xa. Today, none of these drugs is effective enough in every aspect. The need for new antithrombin drugs, as well as the need for new antiplatelet drugs which can be safely and effectively used together with other antithrombin drugs, persists.
authors.affiliation: Department of Cardiology, Medical Faculty, Ege University, Izmir, Turkey. serdar.payzin@ege.edu.tr
authors.forename: Serdar
authors.initials: S
authors.lastname: Payzin
mesh_terms: D000991:Antithrombins / Q000008:administration & dosage / Q000627:therapeutic use*; D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D000991:Antithrombins; D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight; D014812:Vitamin K